Gustavsberg's Vårdcentral
Stockholm, 134 40, Sweden
NCT Number: NCT05032547
We will evaluate a transdiagnostic digital emotion regulation treatment for youth with mental health problems.
Looking for future studies?
Notify Me12 year–17 year
All sexes
Interventional
Not applicable
Stockholm, 134 40, Sweden
Mental health problems in youth are a global problem, causing incalculable suffering in youth and families, harming long-term prospects of youths, and are creating substantial economic costs to society. Existing treatments are not fully addressing these problems because they focus on a subset of mental health problems; they are limited in efficacy; and are not provided to most youth in need. Transdiagnostic digital treatments that address mechanisms underlying mental health problems, such as emotion regulation, have been called for to address these problems. As an initial pilot study we will include 60 participants aged 12-17 years and their parents in a randomized controlled feasibility trial comparing a 6-week Primary care Online Emotion-regulation Treatment (POET) to a 6-week active Supportive Treatment (ST). Both interventions will be delivered in blended format combining online therapist-supported treatment modules with a video-link session. The primary study aims are to examine the feasibility and acceptability of study protocol and treatment protocols. Preliminary utility of the experimental condition will be evaluated by youth-reported, parent-reported, and clinical-reported outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Please see description of experimental arm (arm one)
Please see description of active comparator arm (arm two)
Time frame: End of treatment 6 weeks after baseline
Completion of follow-up will be defined as completing at least one clinical outcome at end of intervention.
Time frame: End of treatment 6 weeks after baseline
We will determine the fraction of potential participants as the number of eligible persons compared to the number of randomized persons.
Time frame: End of treatment 6 weeks after baseline
Compliance with the experimental intervention will be defined as completing at least three of six modules/sessions.
Time frame: Change from baseline, once every week during treatment (0-6 weeks after baseline)
Measure of emotion regulation
Time frame: Change from baseline, once every week during treatment (0-6 weeks after baseline)
Measure of anxiety and depression symptoms
Time frame: Change from baseline, 6 weeks after treatment starts
Measure of global functioning
Time frame: Change from baseline, 6 weeks after treatment starts
Measure of youth strengths and difficulties
Time frame: Change from baseline, 6 weeks after treatment starts
Measure of difficulties in emotion regulation
Time frame: Change from baseline, 6 weeks after treatment starts
Measure of difficulties in cognitive reappraisal and suppression
Time frame: Change from baseline, 6 weeks after treatment starts
Measure of beliefs about emotions
Time frame: Change from baseline, 6 weeks after treatment starts
Measure of emotion regulation flexibility
Region Stockholm
Other Gov
Acronym: POET
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06385457
Adolescents, Body Dissatisfaction
Copenhagen, Copenhagen K, Denmark
View Trial DetailsNCT06000059
Mental Health Issue
Mpunde, Buyende District, Uganda
View Trial DetailsNCT06085105
Adverse Outcomes, Behavior
Navrongo, Ghana
View Trial DetailsNCT04543097
Absence, Behavior
Newcastle-under-Lyme, United Kingdom
View Trial Details